Log In
BCIQ
Print this Print this
 

Vyxeos (CPX-351)

  Manage Alerts
Collapse Summary General Information
Company Jazz Pharmaceuticals plc
DescriptionLiposomal formulation of cytarabine and daunorubicin encapsulated at a 5:1 molar ratio using CombiPlex technology
Molecular Target DNA polymerase ; Topoisomerase II (TOP2)
Mechanism of ActionTopoisomerase II inhibitor; DNA polymerase inhibitor
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,500.0M

$1,500.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/12/2016

$1,500.0M

$1,500.0M

0

Get a free BioCentury trial today